Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Department of Microbiology, Jahangirnagar University, Savar, Dhaka, 1342, Bangladesh.
Harm Reduct J. 2019 Jun 17;16(1):38. doi: 10.1186/s12954-019-0312-8.
Bacterial infection is a major cause of morbidity and mortality for persons who inject drugs (PWID). Injection cessation may help abrogate such infections, but maintaining complete cessation is challenging. Limited data exists on the role of reduced injection intensity on invasive bacterial infection risk. We sought to evaluate decreased risk for bacterial infections following cessation and substantive reduction in the injection intensity.
Participants were persons in the AIDS Linked to the Intravenous Experience (ALIVE) cohort with initial high-frequency injection drug use (> 1 daily). Pooled logistic regression with generalized estimating equations was used to estimate risk for invasive bacterial infection (pneumonia, endocarditis, or sepsis) among participants achieving complete injection cessation or reduced injection intensity relative to those with sustained high-frequency use.
Of 2247 study participants with 12,469 paired study visits, complete injection cessation was achieved at 13.5% and reduced injection intensity at 25.5% of study visits. Adjusting for sociodemographics and HIV status, injection cessation was associated with a 54% reduction of bacterial infection at 3 months (odds ratio [OR] 0.46, 95% CI 0.25-0.84) and a 46% reduction at 6 months (OR 0.54, 95% CI 0.36-0.81). Reduced injection intensity was associated with a 36% reduction of infection at 3 months (OR 0.64, 95% CI 0.43-0.96) and a 26% reduction at 6 months (OR 0.74, 95% CI 0.56-0.98).
Both complete cessation and reduced injection frequency demonstrate substantial benefit in reducing invasive bacterial infection risk among PWID. With high rates of relapse into injection use, targeting sustained reductions in drug use intensity may be a key harm reduction modality for improving clinical outcomes in this population.
细菌感染是导致注射吸毒者(PWID)发病和死亡的主要原因。停止注射可能有助于消除此类感染,但完全停止注射具有挑战性。关于减少注射频率对侵袭性细菌感染风险的影响,目前数据有限。我们旨在评估停止注射和实质性减少注射频率后细菌感染风险降低的情况。
参与者为 AIDS Linked to the Intravenous Experience(ALIVE)队列中最初高频注射吸毒者(> 1 次/天)。采用广义估计方程的汇总逻辑回归来估计与持续高频使用相比,实现完全停止注射或减少注射强度的参与者发生侵袭性细菌感染(肺炎、心内膜炎或败血症)的风险。
在 2247 名研究参与者的 12469 对研究访视中,有 13.5%的参与者完全停止注射,25.5%的参与者减少了注射强度。调整社会人口统计学和 HIV 状况后,在 3 个月时,停止注射与细菌感染减少 54%相关(比值比 [OR] 0.46,95%置信区间 [CI] 0.25-0.84),在 6 个月时,感染减少 46%(OR 0.54,95% CI 0.36-0.81)。减少注射强度与 3 个月时感染减少 36%相关(OR 0.64,95% CI 0.43-0.96),在 6 个月时感染减少 26%(OR 0.74,95% CI 0.56-0.98)。
完全停止和减少注射频率都能显著降低 PWID 侵袭性细菌感染的风险。由于复发率较高,针对药物使用强度的持续降低可能是改善该人群临床结局的关键减少伤害模式。